

Best Available Copy

AMENDMENTS

IN THE SPECIFICATION

Please amend the Cross-Reference to Related Applications on page 1 as follows:

This is a divisional application of U.S.S.N. 09/602,183, filed on June 22, 2000, now U.S. Patent No. 6,576,618 B1, which claims benefit of priority of provisional application U.S. Serial No. 60/140,196, filed June 22, 1999, now abandoned.

Please amend the figure description for Figure 4 on page 11 as follows:

Figures 4A and 4B show[[s]] histologic sections of skin after histochemical reaction for β -galactosidase activity and counterstained with eosin. (Figure 4A). A finely granular blue-green reaction product is present within many myofibroblastic and histiocytic cells in the granulation tissue underlying the burn wound. Magnification x 380. (Figure 4B). Saline-injected (control) dermal tissue underlying uninjured skin near the burn wound showed no reaction product. Magnification x 380.

Please amend the figure description for Figure 12 on page 13 as follows:

Figures 12A and 12B show[[s]] that the presence of β -galactosidase protein was detected by chemiluminescent reporter gene assay in skin biopsies I, II and III. (Figure 12A) Rats receiving single injection of the cDNA construct demonstrated a significant decrease in β -galactosidase expression along the wound edge. * Significant difference between skin biopsy I vs. III, $p < 0.05$. (Figure 12B) Rats receiving multiple injections demonstrated consistent elevated levels of β -galactosidase expression. There was no differences between skin biopsy I, II or III. Data presented as means \pm SEM.

Please amend the figure description for Figure 13 on page 14 as follows:

Figures 13A and 13B show[[s]] the IGF-I protein concentration in skin biopsies I, II and III that was measured by RIA. (Figure 13A) Rats receiving a single injection demonstrated a decrease in IGF-I concentration from biopsy I to III. * Significant difference between skin biopsy I vs. III, $p < 0.05$. (Figure 13B)

BEST AVAILABLE COPY

Animals receiving multiple injections demonstrated consistent high levels of IGF-I. Data presented as means \pm SEM.